NEJM:更高效的非小细胞肺癌(NSCLC)药物Ceritinib出现(临床1期)

来源: 2014-03-27 17:24:32 [博客] [旧帖] [给我悄悄话] 本文已被阅读:

肺癌靶向治疗的更为高效的药物出现了。诺华研发的Ceritinib是一种ALK (anaplastic lymphoma kinase) 抑制剂,体外试验显示,其ALK抑制效能高出克里唑蒂尼(crizotinib)20倍。今天出版的新英格兰医学杂志 (NEJM) 发表了Ceritinib 的临床1期研究结果:对克里唑蒂尼耐药的ALK-重排NSCLC患者,服用Ceritinib后所产生的治疗应答率高达56%。

论文链接: A More Potent ALK Inhibitor in Lung Cancer

Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in 56% of those who had resistance to crizotinib.

A More Potent ALK Inhibitor in Lung Cancer
 
-------------------------------------------------------------------------------------------------

肺癌分类图




新药的四期临床试验(从下往上看~.~)